ArticleFrontiers in oncology2015

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer.

Jung-Min Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.